Drug
Ose2101
Ose2101: highest development phase Phase 3, developed by OSE Immunotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- OSE Immunotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| OSE2101 NCT06472245 | Phase 3 | Patients With Non-Small Cell Lung Cancer |
Latest
No recent events.
Follow Ose2101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.